A61K 2039/55544
Bacterial toxins
Official title: {Bacterial toxins}
A61K2039/55544 (Bacterial toxins) appears on 383 US grants and 656 published applications in this corpus.
Search patents in A61K- Granted patents
- 383
- Published applications
- 656
- Assignees
- 368
- Inventors
- 1,270
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 3 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 8 | 0 |
| 2000 | 9 | 0 |
| 2001 | 7 | 5 |
| 2002 | 14 | 15 |
| 2003 | 4 | 16 |
| 2004 | 9 | 35 |
| 2005 | 3 | 19 |
| 2006 | 15 | 32 |
| 2007 | 6 | 24 |
| 2008 | 9 | 29 |
| 2009 | 14 | 31 |
| 2010 | 13 | 37 |
| 2011 | 9 | 36 |
| 2012 | 19 | 23 |
| 2013 | 14 | 14 |
| 2014 | 18 | 34 |
| 2015 | 22 | 34 |
| 2016 | 22 | 25 |
| 2017 | 25 | 27 |
| 2018 | 16 | 25 |
| 2019 | 21 | 27 |
| 2020 | 19 | 18 |
| 2021 | 15 | 30 |
| 2022 | 16 | 24 |
| 2023 | 9 | 31 |
| 2024 | 16 | 30 |
| 2025 | 13 | 15 |
| 2026 | 6 | 20 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for preventing and treating virus infection15 Sep 2026US 12,734,234 B2University of Virginia Patent Foundation
- Tumor immunotherapy composition based on antigen-presenting cells activated by attenuated listeria monocytogenes, preparation method therefor and application thereof11 Aug 2026US 12,702,681 B2Shanghai RoyalTech Med CO., Ltd
- Compositions and methods for metal containing formulations capable of modulating immune response12 May 2026US 12,622,922 B2The Regents of the University of Michigan
- Modified clostridial neurotoxins as vaccine and conjugate vaccine platforms28 Apr 2026US 12,611,464 B2The Medical College of Wisconsin, Inc.
- Method of modulating mucosal immunogenicity31 Mar 2026US 12,589,149 B2Advagene Biopharma Co., Ltd.
- Compositions and methods for generating immunity to bacterial infection8 Oct 2026US 2026/0306601 A1Syntiron LLC
- Saponin dmlt adjuvants and related uses1 Oct 2026US 2026/0295037 A1Q-Vant Biosciences, Inc.
- Hiv vaccine24 Sep 2026US 2026/0284176 A1
- Protein and vaccine against infection by sars-cov-2 omicron variant strain and subtype thereof10 Sep 2026US 2026/0263587 A1Westvac Biopharma Co., Ltd.
- Vaccines against clostridioides difficile and methods of using the same13 Aug 2026US 2026/0232785 A1
Most cited
By later US patents
- Receptor specific transepithelial transport of therapeutics240US 6,485,726 B1Brandeis University · 2002
- Submicron emulsions as vaccine adjuvants129US 5,961,970 APharmos Corporation · 1999
- Vaccine containing tumor antigens and adjuvants126US 4,877,611 ARibi ImmunoChem Research, Inc. · 1989
- Refined detoxified endotoxin107US 4,866,034 ARibi ImmunoChem Research, Inc. · 1989
- Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response90US 6,797,276 B1The United States of America as represented by the Secretary of the Army · 2004